The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for patients with type 1 diabetes who have a kidney transplant.
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors >45 years after brain death (DBD).
The purpose of this study is to determine if coronary artery disease (CAD) screening is necessary for patients on the waiting list for kidney transplantation. Patients on the waiting list for kidney transplantation are at risk for CAD. Currently, patients without any symptoms of CAD undergo annual testing to determine if they have disease. The optimal strategy to monitor and maintain the cardiac fitness of these patients is unknown.
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation have not been achieved. The specific drug combination that provides the best outcomes with the least amount of side effects is not known. Each kidney transplant center uses the combination of drugs that they believe is optimal.